Penarth headquartered and AIM listed global diagnostics business, EKF Diagnostics, has secured three new contracts in the organic growth area of hematology point-of-care testing worth just over £4m.
The contracts, for the supply of hemoglobin analysers and related consumables, have been secured by EKF’s distribution partners in Latin America and Africa. One contract represents a return to significant sales in Peru, following a sharp decline in local sales due to geo-political factors within the country. Another contract marks EKF’s first sales into Uganda, as strong sales growth continues across Africa.
The contracts will be delivered over the next 12 to 24 months.
EKF said it successfully increased supply capacity going into the second half of 2025 to meet rising demand. With the order book already at record levels and now full for 2025, further investment will be deployed to grow hemoglobin consumable and analyser production capacity at its Barleben site in Germany by 30% as part of the five-year strategic development plan for the business.
The additional contracts reinforce the board’s confidence in delivering growth at the revenue and adjusted Ebitda levels for full year 2025 in-line with market expectations. The continued global expansion of EKF’s hematology analyzer footprint also provides confidence in future growth as these continue to drive the pull through of consumables.
Chief executive of EKF, Gavin John, said: aid: “As part of our five-year strategic development plan to support accelerated organic growth, we identified that Hemoglobin testing was the most significant growth opportunity within our point of care (POC) portfolio.
"We’re very pleased to see that allowing our dedicated POC sales team to focus on core growth products is bearing fruit, particularly in Hemoglobin point of care testing. As we win more and more new contracts and increase our global analyser footprint, we will see the benefits not just this year, but also in the years to come as consumable pull-through drives higher margin revenue growth.”
The company remains on track to deliver growth at the revenue and adjusted Ebitda levels for 2025 in-line with market expectations of £53.6m and £12.4m respectively.6
